使用DepMap优先考虑癌症类型特定的治疗脆弱性的新管道将PAK2确定为头部和部状细胞癌的标
Malay K Sannigrahi1, Austin C Cao1, Pavithra Rajagopalan1
1Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.
Molecular oncology
|November 24, 2023
概括
这项研究提出了一个新的管道,用于使用CRISPR屏幕从依赖地图 (DepMap) 找到癌症药物标. 对于头部和部状细胞癌 (HNSCC),它确定了PAK2作为一个有前途的治疗标.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 在癌症依赖图 (DepMap) 中的全基因组功能丧失CRISPR屏幕提供了识别新型癌症标的潜力.
- 对于有效利用这些针对特定癌症类型的查方法,存在有限的指导.
研究的目的:
- 开发和应用一个计算管道,以使用DepMap数据优先确定头部和部状细胞癌 (HNSCC) 的治疗相关目标.
- 确定可操作的治疗目标和潜在的药物重定向机会,用于HNSCC.
主要方法:
- 集成多个计算工具来过和优先考虑基因从全基因组的CRISPR屏幕.
- 将管道应用于DepMap数据的头部和部状细胞癌 (HNSCC).
- 分析了抑制剂反应数据,以验证优先目标并确定生物标志物.
主要成果:
- 在HNSCC中优先考虑了143个可向的依赖性,包括已知和新的目标类.
- 确定了14个具有现有临床抑制剂的标,适合在HNSCC.中重新定位.
- 发现了PAK2 (氨酸/氨酸激酶) 作为一种新的治疗点,依赖性与野生类型的p53,低PAK2mRNA和3q安普利康双胞胎状态有关.
结论:
- 从DepMap数据建立了一个可概括的管道,以优先考虑癌症特定的治疗目标.
- 突出了PAK2抑制作为HNSCC治疗的有希望的策略.
- 在HNSCC中预测PAK2抑制剂反应的已确定生物标志物.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.2K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
